Less increase of copeptin and MR‐proADM due to intervention with selenium and coenzyme Q10 combined: Results from a 4‐year prospective randomized double‐blind placebo‐controlled trial among elderly Swedish citizens. (10th December 2015) - Alehagen, Urban
Abstract: Intervention with selenium and coenzyme Q10 have recently been found to reduce mortality and increase cardiac function. The mechanisms behind these effects are unclear. As selenium and coenzyme Q10 is involved in the anti‐oxidative defence, the present study aimed to evaluate effects of selenium and coenzyme Q10 on copeptin and adrenomedullin as oxidative stress biomarkers. Therefore 437 elderly individuals were included and given intervention for 4 years. Clinical examination and blood samples were undertaken at start and after 18 and 48 months. Evaluations of copeptin and MR‐proADM changes were performed using repeated measures of variance. Cardiovascular mortality was evaluated using a 10‐year‐period of follow‐up, and presented in Kaplan‐Meier plots. A significant increase in copeptin level could be seen in the placebo group during the intervention period (from 9.4 pmol/L to 15.3 pmol/L), compared to the active treatment group. The difference between the groups was confirmed in the repeated measurement of variance analyses ( P = 0.031) with less copeptin increase in the active treatment group. Furthermore, active treatment appeared to protect against cardiovascular death both in those with high and with low copeptin levels at inclusion. Less increase of MR‐proADM could also be seen during the intervention in the active treatment group compared to controls ( P =0.026). Both in those having an MR‐proADM level above or below median level, significantly less cardiovascular mortality could be seen in the active treatment group ( P =0.0001, and P =0.04 respectively). In conclusion supplementation with selenium and coenzyme Q10 during four years resulted in less concentration of both copeptin and MR‐proADM. A cardioprotective effect of the supplementation was registered, irrespective of the initial levels of these biomarkers, and this protection was recognized also after 10 years of observation. © 2015 BioFactors, 41(6):443–452, 2015